Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY: LLY )

584.04 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EST, Dec 1, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,902
Open 584.04
Bid (Size) 584.55 (2)
Ask (Size) 584.95 (1)
Prev. Close 584.04
Today's Range 584.04 - 584.04
52wk Range 302.14 - 629.97
Shares Outstanding N/A
Dividend Yield 0.77%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
3 No-Brainer Growth Stocks to Buy in December
No analysis paralysis is required with these great stocks. 
Via The Motley Fool
Pfizer Tumbles After Abandoning Weight-Loss Pill
With shares already reflecting a post-COVID dearth of revenue streams, Pfizer's growth outlook recently took another hit as it halted development of its experimental weight-loss pill after a high rate... 
Via Talk Markets

Performance

YTD
+60.02%
+60.02%
1 Month
+2.86%
+2.86%
3 Month
+4.63%
+4.63%
6 Month
+28.66%
+28.66%
1 Year
+58.15%
+58.15%

More News

Read More
An Important History Lesson for Gene-Editing Investors
Via The Motley Fool
Is Eli Lilly a Better Stock to Buy and Hold Over the Next 10 Years Than Novo Nordisk?
Via The Motley Fool
5 Top Stocks to Buy Before 2024
Via The Motley Fool
Weight Loss Drugs And Associated Suicidal Thoughts - European Drug Regulator Seeks Clarifications From Drug Makers
Via Benzinga
If You Invested $100 In This Stock 10 Years Ago, You Would Have $1,200 Today
Via Benzinga
Eli Lilly's Options: A Look at What the Big Money is Thinking
Via Benzinga
Weight Loss Drugs - Novo Nordisk A Primary Beneficiary In Obesity Space Currently Controlled By Two Players, Says Analyst
Via Benzinga
Pfizer Halts Development Of Twice-Daily Weight-Loss Drug; PFE Stock Slides
Via Investor's Business Daily
Dow Jones Hits 2023 High, Nasdaq Slips; Tesla Cybertruck, Salesforce In Focus: Weekly Review
Via Investor's Business Daily
Topics Economy Stocks
Exposures Interest Rates US Equities
Pfizer’s Stock Is Down 44% YTD As Woes Continue
Via Talk Markets
Elliott Wave Technical Analysis: Eli Lilly & Co.
Via Talk Markets
1 Underrated Reason to Buy Eli Lilly Stock
Via The Motley Fool
Novo Nordisk Sues Florida Compounding Pharmacies Over Impurities In Products Claiming To Contain Wegovy Ingredient
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
Eli Lilly's Weight-Management Drug Outperformed Ozempic. Is It Time to Buy?
Via The Motley Fool
Anti-Inflammatory Drugs Market Boosting the Growth Worldwide 2030
Via SBWire
Improving Survival Rates: Biotech Innovations in Pancreatic Cancer Treatment
Via FinancialNewsMedia
Topics Death
Exposures Death
Counterfeit Ozempic Raises Alarms - Lebanon Reports Hypoglycemia Cases
Via Benzinga
These are the top sectors for blue chip growth in 2024
Via MarketBeat
Topics Economy Intellectual Property
Exposures COVID-19 Intellectual Property Interest Rates
Ozempic Receives Some Very Bad News: Is It Time to Sell Novo Nordisk Stock?
Via The Motley Fool
Lilly's Weight-Loss Drug Wallops Novo's In Head-To-Head Study; Novo Stock Dives
Via Investor's Business Daily
Eli Lilly's Blockbuster Mounjaro Shows Larger, Faster Weight Loss Than Novo Nordisk's Ozempic In Real World Study
Via Benzinga
Biotech And Healthcare Portfolio Playbook For December 2023/24
Via Talk Markets
Novo Nordisk's Flexible Pricing Approach: Push for Broader Access, Innovative Payments
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.